UCB’s epilepsy treatment Briviact enters Brazil under alias

GBI analysis shows that Brazil’s National Health Surveillance Agency (ANVISA) last week nodded Belgium-based UCB Pharma’s Brivlera (brivaracetam). The tablets are indicated as adjunctive therapy in the treatment of partial-onset seizures in patients with epilepsy.

Although Brivlera’s mechanism of action is not fully understood, it seems to involve synaptic vesicle protein 2A (SV2A), which is located in neurons and endocrine cells. Because this transmembrane protein is known to modulate the release of neurotransmitters from one signalling cell to another, it is believed that the drug’s high and selective affinity for SV2A is responsible for its anticonvulsant activity.

GBI analysis reveals that Brivlera is currently registered under the brand name Briviact in Colombia and Mexico, as well as in Argentina, where it obtained approval only after Argentina-based laboratory Monte Verde’s generic version Brivaxon, as GBI reported. In addition, Monte Verde’s product dominates the Peru market.


Related news
Colombia’s National Food and Drug Surveillance Institute (INVIMA) last week granted registration approval to Belgium-based UCB Pharma’s Briviact (brivaracetam), according to GBI analysis.
According to GBI analysis, Argentina’s National Administration of Drugs, Foods and Medical Devices (ANMAT) this week published its February approval of Argentina-based laboratory Monte Verde’s generic Brivaxon (brivaracetam), the only such medicine registered in the country.
Recent news
Zulema Tomás Gonzáles, head of Peru’s Ministry of Health (MINSA), this week announced that she will pressure President Martín Vizcarra to approve through emergency decrees two draft laws aimed at improving health access.
Bayer Consumer Health opened its first Asia-Pacific R&D center, located in Qidong, Jiangsu, China.
Guillaume Corpart, managing director of hospital statistics firm Global Health Intelligence, said during an interview with the Mexico Health Review that recent changes in Mexico’s public sector are putting pressure on drug and medical supplies providers.
Shenzhen-based Ionova Life Science Co., Ltd announced a successful RMB 126 million (USD 17.8 million) in a Series A financing round, led by Lilly Asia Ventures, with DYEE Capital participating.
Swiss major Novartis and Brazil’s Oswaldo Cruz Foundation (Fiocruz) signed a memorandum of understanding (MoU) to cooperate in research and development (R&D) and education projects to combat neglected diseases such as Hansen's disease (HD), Chagas disease, malaria, and sickle cell disease.
China Grand Pharmaceutical and Healthcare Holdings Ltd (CGP) is moving to take a sizeable stake in US-headquartered biotech OncoSec Medical Inc. An agreement has been reached for CGP to acquire 44.2% of OncoSec for USD 25 million, subject to shareholder approval, with an option to fully buy out the company within 12 months.
  • 1571120805603
  • China
The Implementation Plan for the “Two Invoices” System in Public Medical Institutions Drug Procurement” was jointly released by several ministries in Shandong, led by the Health Commission bureau, as well as the Development and Reform Commission, the Healthcare Security Administration, and others.
Analytics Snapshot

Analytics Snapshot